Advertisement
U.S. markets open in 7 hours 45 minutes

Immutep Limited (IMMP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.4200+0.0300 (+1.26%)
At close: 04:00PM EDT
2.4000 -0.02 (-0.83%)
After hours: 04:51PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close2.3900
Open2.3500
Bid2.4200 x 800
Ask2.8400 x 900
Day's Range2.3500 - 2.4400
52 Week Range1.5000 - 3.9000
Volume65,781
Avg. Volume134,818
Market Cap287.697M
Beta (5Y Monthly)1.81
PE Ratio (TTM)N/A
EPS (TTM)-0.2600
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.58
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IMMP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Immutep Limited
    Daily – Vickers Top Buyers & Sellers for 02/22/2024The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    26 days agoArgus Research
View more
  • GlobeNewswire

    Immutep Announces First Clinical Data from 90mg Dosing of Efti

    Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and well toleratedEncouraging initial efficacy in six metastatic breast cancer patients, who exhausted all endocrine therapy including CDK4/6 inhibitors, demonstrated by a 50% overall response rate, including one complete response, and a 100% disease control rate SYDNEY, AUSTRALIA, March 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a cl

  • Simply Wall St.

    Individual investors account for 60% of Immutep Limited's (ASX:IMM) ownership, while institutions account for 29%

    Key Insights Immutep's significant individual investors ownership suggests that the key decisions are influenced by...

  • Insider Monkey

    10 Best Australian Stocks To Buy

    In this piece, we will take a look at the ten best Australian stocks to buy. If you want to skip our coverage of some of the biggest stocks in Australia and how you might trade them, then you can skip ahead to 5 Best Australian Stocks To Buy. When we talk about the fundamentals […]